Use of PDE7 inhibitors for the treatment of movement disorders

US8637528B2 · kind B2 · utility

Assignee

• Omeros Corporation · US

Inventors

• John E. Bergmann · Albany, US
• Neil S. Cutshall · Snohomish, US
• Gregory A. Demopulos · Mercer Island, US
• Vincent A. Florio · Seattle, US
• George A. Gaitanaris · Seattle, US
• Patrick Gray · San Francisco, US
• John Hohmann · Seattle, US
• Rene Onrust · Mercer Island, US
• Hongkui Zeng · Shoreline, US

Key dates

• Filing date: May 4, 2009
• Grant date: Jan 28, 2014
• Expiry date: Jun 13, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

A method of treating a movement abnormality associated with the pathology of a neurological movement disorder, such as Parkinson's disease or Restless Leg(s) Syndrome by administering a therapeutically effective amount of a PDE7 inhibitory agent. An aspect of the invention provides for the administration of a PDE& inhibitory agent in conjunction with a dopamine agonist or precursor, such as levodopa. In another aspect of the invention, the PDE7 inhibitory agent may be selective for PDE7 relative to other molecular targets (i) known to be involved with the pathology of Parkinson's disease or (ii) at which other drug(s) that are therapeutically effective to treat Parkinson's disease act.